{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T01:06:07Z","timestamp":1773277567125,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.trim.2017.09.003","type":"journal-article","created":{"date-parts":[[2017,9,23]],"date-time":"2017-09-23T16:30:54Z","timestamp":1506184254000},"page":"59-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Ibrutinib suppresses alloantibody responses in a mouse model of allosensitization"],"prefix":"10.1016","volume":"45","author":[{"given":"Irene","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordon","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning-ning","family":"Chai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew S.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanley","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.trim.2017.09.003_bb0005","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/ejh.12427","article-title":"B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells","volume":"94","author":"Seda","year":"2015","journal-title":"Eur. J. Haematol."},{"issue":"4","key":"10.1016\/j.trim.2017.09.003_bb0010","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2174\/1871525712666140115143914","article-title":"Ibrutinib: a new frontier in the treatment of chroniclymphocytic leukemia by Bruton's tyrosine kinase inhibition","volume":"11","author":"Dias","year":"2013","journal-title":"Cardiovasc. Hematol. Agents Med. Chem."},{"issue":"1","key":"10.1016\/j.trim.2017.09.003_bb0015","doi-asserted-by":"crossref","first-page":"58","DOI":"10.4049\/jimmunol.1600208","article-title":"Enhanced expression of Bruton's tyrosine kinase in B cells drives systemic autoimmunity by disrupting T cell homeostasis","volume":"197","author":"Corneth","year":"2016","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.trim.2017.09.003_bb0020","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.trim.2017.09.003_bb0025","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1053\/j.seminoncol.2016.02.008","article-title":"Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia","volume":"43","author":"Maddocks","year":"2016","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.trim.2017.09.003_bb0030","doi-asserted-by":"crossref","DOI":"10.1007\/s40265-017-0695-3","article-title":"Ibrutinib: a review in chronic lymphocytic leukaemia","author":"Deeks","year":"2017","journal-title":"Drugs"},{"issue":"16","key":"10.1016\/j.trim.2017.09.003_bb0035","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1158\/1078-0432.CCR-14-2225","article-title":"FDA approval: ibrutinib for patients with previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukemia","volume":"21","author":"de Claro","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.trim.2017.09.003_bb0040","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1586\/17474086.2015.1061427","article-title":"Ibrutinib for the treatment of Waldenstr\u00f6m macroglobulinemia","volume":"8","author":"Chakraborty","year":"2015","journal-title":"Expert. Rev. Hematol."},{"issue":"1","key":"10.1016\/j.trim.2017.09.003_bb0045","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/imj.13311","article-title":"Treatment of patients with Waldenstr\u00f6m macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group","volume":"47","author":"Talaulikar","year":"2017","journal-title":"Intern. Med. J."},{"key":"10.1016\/j.trim.2017.09.003_bb0050","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1034\/j.1600-6143.2002.20801.x","article-title":"Management of the highly HLA-sensitized patient. A novel role for intravenous gammaglobulin","volume":"2","author":"Jordan","year":"2002","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2017.09.003_bb0055","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1111\/j.1600-6143.2009.02612.x","article-title":"Mechanisms of alloantibody production in sensitized renal allograft recipients","volume":"9","author":"Stegall","year":"2009","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2017.09.003_bb0060","article-title":"Interleukin 6 (IL-6) a cytokine critical to mediation of inflammation, autoimmunity and allograft rejection: therapeutic implications of IL-6 receptor blockade","author":"Jordan","year":"2016","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.trim.2017.09.003_bb0065","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/MOT.0000000000000336","article-title":"Risk factors associated with the development of histocompatibility leukocyte antigen sensitization","volume":"21","author":"Jordan","year":"2016","journal-title":"Curr. Opin. Organ Transplant."},{"issue":"9","key":"10.1016\/j.trim.2017.09.003_bb0070","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1097\/TP.0b013e3182888db6","article-title":"The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes","volume":"95","author":"Freitas","year":"2013","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.trim.2017.09.003_bb0075","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/ajt.12589","article-title":"Diagnosis and management of antibody-mediated rejection: current status and novel approaches","volume":"14","author":"Djamali","year":"2014","journal-title":"Am. J. Transplant."},{"issue":"3\u20134","key":"10.1016\/j.trim.2017.09.003_bb0080","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.trim.2008.05.004","article-title":"Anti-CD20 antibody suppresses anti-HLA antibody formation in a HLA-A2 transgenic mouse model of sensitization","volume":"19","author":"Wu","year":"2008","journal-title":"Transpl. Immunol."},{"issue":"12","key":"10.1016\/j.trim.2017.09.003_bb0085","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1097\/TP.0000000000000437","article-title":"Anti-interleukin 6 receptor antibodies attenuate antibody recall responses in a mouse model of allosensitization","volume":"98","author":"Kim","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2017.09.003_bb0090","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.trim.2016.08.001","article-title":"Immunological characterization of de novo and recall alloantibody suppression by CTLA4Ig in a mouse model of allosensitization","volume":"38","author":"Kim","year":"2016","journal-title":"Transpl. Immunol."},{"issue":"9","key":"10.1016\/j.trim.2017.09.003_bb0095","doi-asserted-by":"crossref","first-page":"e0137641","DOI":"10.1371\/journal.pone.0137641","article-title":"Inhibition of BTK and ITK with ibrutinib is effective in the prevention of chronic graft-versus-host disease in mice","volume":"10","author":"Schutt","year":"2015","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.trim.2017.09.003_bb0100","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1172\/JCI75328","article-title":"Ibrutinib treatment ameliorates murine chronic graft-versus-host disease","volume":"124","author":"Dubovsky","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.trim.2017.09.003_bb0105","doi-asserted-by":"crossref","first-page":"222","DOI":"10.4049\/jimmunol.1200677","article-title":"cells in transplants augment clonal expansion and survival of pathogenic CD4+ T cells that mediate autoimmune-like chronic graft-versus-host disease","volume":"189","author":"Young","year":"2012","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.trim.2017.09.003_bb0110","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1111\/ajt.13838","article-title":"De novo donor-specific human leukocyte antigen antibody screening in kidney transplant recipients after the first year posttransplantation: a medical decision analysis","volume":"16","author":"Kiberd","year":"2016","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2017.09.003_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.kint.2016.10.040","article-title":"Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent\/recurrent versus de novo donor-specific antibodies","author":"Haas","year":"2017","journal-title":"Kidney Int."},{"key":"10.1016\/j.trim.2017.09.003_bb0120","doi-asserted-by":"crossref","first-page":"5197396","DOI":"10.1155\/2016\/5197396","article-title":"The humoral theory of transplantation: epitope analysis and the pathogenicity of HLA antibodies","volume":"2016","author":"Filippone","year":"2016","journal-title":"J Immunol Res"},{"issue":"12","key":"10.1016\/j.trim.2017.09.003_bb0125","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1182\/blood-2016-04-709519","article-title":"Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4\/SDF-1 axis","volume":"128","author":"Pavlasova","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.trim.2017.09.003_bb0130","doi-asserted-by":"crossref","first-page":"557","DOI":"10.4049\/jimmunol.152.2.557","article-title":"Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells","volume":"152","author":"Smith","year":"1994","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.trim.2017.09.003_bb0135","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1002\/eji.1830231210","article-title":"The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages","volume":"23","author":"de Weers","year":"1993","journal-title":"Eur. J. Immunol."},{"issue":"10","key":"10.1016\/j.trim.2017.09.003_bb0140","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1084\/jem.193.10.1169","article-title":"Bruton's tyrosine kinase regulates the activation of gene rearrangements at the lambda light chain locus in precursor B cells in the mouse","volume":"193","author":"Dingjan","year":"2001","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.trim.2017.09.003_bb0145","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1073\/pnas.050583597","article-title":"Posttranscriptional regulation of Bruton's tyrosine kinase expression in antigen receptor-stimulated splenic B cells","volume":"97","author":"Nisitani","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.trim.2017.09.003_bb0150","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/ajh.23433","article-title":"Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease","volume":"88","author":"Bam","year":"2013","journal-title":"Am. J. Hematol."},{"issue":"4","key":"10.1016\/j.trim.2017.09.003_bb0155","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/leu.2015.316","article-title":"BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia","volume":"30","author":"Chen","year":"2016","journal-title":"Leukemia"}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327417300953?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327417300953?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T08:44:41Z","timestamp":1693039481000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966327417300953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":31,"alternative-id":["S0966327417300953"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2017.09.003","relation":{},"ISSN":["0966-3274"],"issn-type":[{"value":"0966-3274","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ibrutinib suppresses alloantibody responses in a mouse model of allosensitization","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2017.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}